PropertyValue
?:definition
  • An orally bioavailable inhibitor of the proto-oncogene hepatocyte growth factor receptor (c-Met; HGFR), with potential antineoplastic activity. Upon administration, CBT-101 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in c-Met-overexpressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis. Check for \'https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C150675\' active clinical trials using this agent. (\'http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C150675\' NCI Thesaurus)
?:hasCUIAnnotation
?:hasGeneratedBy
?:type

Metadata

Anon_0  
expand all